Eur Rev Med Pharmacol Sci 2018; 22 (11): 3430-3438

DOI: 10.26355/eurrev_201806_15166

MicroRNA-1266 suppresses papillary thyroid carcinoma cell metastasis and growth via targeting FGFR2

Y.-T. Fu, H.-B. Zheng, D.-Q. Zhang, L. Zhou, H. Sun

Department of Thyroid Surgery, China-Japan Union Hospital of Jilin University, Changchun, China. Haibozheng86@sina.com


OBJECTIVE: To explore the effects of microRNA-1266 (miR-1266) on metastasis and growth in papillary thyroid carcinoma cells and to provide therapeutic targets for papillary thyroid carcinoma.

PATIENTS AND METHODS: By quantitative Real-time polymerase chain reaction (PCR), miR-1266 expression level in 38 pairs of papillary thyroid carcinoma tissues and three breast cancer-derived cell lines was examined. After transfection with miR-1266 mimics, the effects of miR-1266 over-expression on cell proliferation, invasion and migration were analyzed. Further, we employed several databases for the target gene prediction. Dual-luciferase activity assay was performed to verify whether FGFR2 was the direct target gene of miR-1266. Western blotting was conducted to detect protein levels.

RESULTS: MiR-1266 was significantly downregulated in papillary thyroid carcinoma tissue samples and cell lines. Over-expression of miR-1266 in papillary thyroid carcinoma cells significantly attenuated the cell proliferation, invasion, and migration. Dual-luciferase report assay and Western blotting confirmed that FGFR2 was a target gene of miR-1266. Furthermore, up-regulation of FGFR2 partially reversed the suppressive effects of miR-1266 over-expression on cell growth and progression.

CONCLUSIONS: miR-1266 could inhibit cell proliferation and progression of papillary thyroid carcinoma via targeting FGFR2. Our findings might provide a new target for the diagnosis and treatment of papillary thyroid carcinoma.

Free PDF Download

To cite this article

Y.-T. Fu, H.-B. Zheng, D.-Q. Zhang, L. Zhou, H. Sun
MicroRNA-1266 suppresses papillary thyroid carcinoma cell metastasis and growth via targeting FGFR2

Eur Rev Med Pharmacol Sci
Year: 2018
Vol. 22 - N. 11
Pages: 3430-3438
DOI: 10.26355/eurrev_201806_15166